Liu Dan, Zhang Yi-Fei
Dan Liu Department of Neonatology, Associate Chief Physician, Associate Professor, The First Affiliated Hospital of Yangtze University, Jingzhou 434000, Hubei, China. The First Clinical Medical Collage of Yangtze University, Jingzhou 434000, Hubei, China.
Yi-fei Zhang Department of Pediatric Medicine, Chief Physician, The First Affiliated Hospital of Yangtze University, Jingzhou 434000, Hubei, China.
Pak J Med Sci. 2024 Oct;40(9):2124-2129. doi: 10.12669/pjms.40.9.8942.
To investigate the clinical efficacy of roxithromycin combined with azithromycin sequential therapy in the treatment of mycoplasma pneumoniae pneumonia in children.
A retrospective study was conducted on 100 patients with mycoplasma pneumoniae pneumonia admitted to The First Affiliated Hospital of Yangtze University from January 2020 to December 2022. All patients were divided into the observation group (roxithromycin combined with azithromycin sequential therapy) and the control group (azithromycin sequential therapy), with 50 cases in each group. The clinical efficacy, improvement time of clinical symptoms/signs, inflammation indexes, oxidative stress indexes and immune function levels of the two groups were compared. Moreover, the improvement of lung function indexes and the adverse reactions were observed.
The overall response rate of the observation group was 96.00%, which was higher than the control group (84.00%) (0.05). The time of clinical symptoms/signs in the observation group were significantly lower than those in the control group(0.05). After treatment, significant improvements were seen in the levels of CRP, TNF-ɑ, IL-6, GSH-Px, SOD, MDA, CD3, CD4, CD4/CD8, IgM, IgG , IgA, FEV, FEV%, FVC and FEV/FVC of the two groups compared with those before treatment (0.05), and the improvement in the observation group was more obvious than that in the control group(0.05). The overall incidence of adverse reactions in the observation group was 6.00%, which was slightly lower than that in the control group (8.00%) (c²=0.154, =0.695).
Roxithromycin combined with azithromycin sequential therapy is a safe regimen for the treatment of mycoplasma pneumoniae pneumonia in children.
探讨罗红霉素联合阿奇霉素序贯疗法治疗儿童支原体肺炎的临床疗效。
回顾性分析2020年1月至2022年12月在长江大学附属第一医院收治的100例支原体肺炎患儿的临床资料。将所有患儿分为观察组（罗红霉素联合阿奇霉素序贯疗法）和对照组（阿奇霉素序贯疗法），每组50例。比较两组的临床疗效、临床症状/体征改善时间、炎症指标、氧化应激指标及免疫功能水平。此外，观察肺功能指标的改善情况及不良反应。
观察组总有效率为96.00%，高于对照组（84.00%）（P<0.05）。观察组临床症状/体征改善时间明显短于对照组（P<0.05）。治疗后，两组患儿的CRP、TNF-α、IL-6、GSH-Px、SOD、MDA、CD3、CD4、CD4/CD8、IgM、IgG、IgA、FEV、FEV%、FVC及FEV/FVC水平较治疗前均有明显改善（P<0.05），且观察组改善更明显（P<0.05）。观察组不良反应总发生率为6.00%，略低于对照组（8.00%）（χ²=0.154，P=0.695）。
罗红霉素联合阿奇霉素序贯疗法是治疗儿童支原体肺炎的一种安全方案。
